SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES: P.191 Preliminary data for the cost-effectiveness assessment of the newborn screening for SMA in Belgium

peer reviewed ; Neonatal screening is becoming increasingly important in the spinal muscular atrophy (SMA) landscape. Yet there is a growing set of evidences that early pre-symptomatic management is much more efficient than post- symptomatic treatment, there is however no information available on the cost-effectiveness of SMA newborn screening (NBS). Such health economic analysis is nevertheless very important to convince policy makers to allocate funds for NBS. We will present the health-economic data of pre-symptomatic and post-symptomatic treated patients in Belgium that will further be use... Mehr ...